Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Profit After Tax: 2022-2025

Historic Profit After Tax for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$32.7 million.

  • Taysha Gene Therapies' Profit After Tax fell 28.24% to -$32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 338.82%. This contributed to the annual value of -$89.3 million for FY2024, which is 19.96% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Profit After Tax is -$32.7 million, which was down 21.77% from -$26.9 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Profit After Tax ranged from a high of $47.7 million in Q4 2023 and a low of -$117.1 million during Q3 2023.
  • Over the past 3 years, Taysha Gene Therapies' median Profit After Tax value was -$24.1 million (recorded in 2024), while the average stood at -$25.6 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Profit After Tax in the last 5 years was 186.68% (2023), contrasted with its biggest fall of 341.39% (2023).
  • Taysha Gene Therapies' Profit After Tax (Quarterly) stood at -$55.1 million in 2022, then soared by 186.68% to $47.7 million in 2023, then slumped by 139.35% to -$18.8 million in 2024, then decreased by 28.24% to -$32.7 million in 2025.
  • Its Profit After Tax was -$32.7 million in Q3 2025, compared to -$26.9 million in Q2 2025 and -$21.5 million in Q1 2025.